A Phase 3 interventional study of Testing of hepatic AAV Vector integration in Hemophilia A and Hemophilia B, sponsored by Pfizer. Recruiting at 44 sites in 14 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Pfizer · Phase 3, Interventional, and Other
France, Germany, Greece, Japan, Saudi Arabia, Spain, Brazil
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in Hemophilia A by Pfizer — 6 open to participants now, 9 under way, 6 of them phase 3. Hemophilia A · Pfizer.
Among the 47 studies in Hemophilia A by Pfizer, this one is the 5th largest by planned enrollment of the 32 interventional ones that give a count, is one of 2 that started in 2022, is one of 15 in phase 3, and was the 41st registered.
845 studies on the registry are indexed under Hemophilia A; 137 are open to participants now.
Browse Hemophilia A studies →6 of the 47 studies in Hemophilia A by Pfizer are open now, in 12 countries. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 6+
Pfizer · Sites in United States
Ages 12–74
Pfizer · Sites in United States, India, Turkey
Ages 12–74 · Men only
Pfizer · Sites in United States, Argentina, Australia and 19 more countries
Ages 1–17 · Men only
Pfizer · Sites in United States, Argentina, Australia and 21 more countries
Ages 1–74 · Men only
By country, each count listing its studies:
Of the 88 Hemophilia A studies recruiting now, 52 (59%) set no upper age limit and 31 (35%) stop at 75 or younger; 56 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
First in 1994; this study’s year is marked. 2 started in 2022.
This study's planned enrollment of 173 is above the median of 30 across 499 interventional studies indexed under Hemophilia A.
Median enrollment 34 across the 32 interventional studies, 52 across the 13 observational. Of the 34 that completed or were terminated, 25 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,338 studies on the registry; 147 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 393 (65%) have results posted.
1 of the studies in Hemophilia A by Pfizer that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06703606PfizerA Study to Learn About How Changing Therapy From Emicizumab to Marstacimab Affects People With the Severe Hemophilia A. | 2027-05-05 |
Add it to your calendar (.ics) → With an account.
Among the 47 studies in Hemophilia A by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A study to learn about the long-term safety and efficacy of giroctocogene fitelparvovec or fidanacogene elaparvovec in patients with hemophilia A or hemophilia B respectively, who have received treatment through prior participation in a Pfizer-sponsored clinical trial. Data collection and participant visits will be based on standard of care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
-Only participants who received giroctocogene fitelparvovec or fidanacogene eleparvovec and were enrolled in a Pfizer-sponsored study (C0371002, C0371003, C0371005, C3731001, C3731003) are eligible.
Exclusion Criteria:
-None
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants have received treatment with giroctocogene fitelparvovec in a previous study and are not receiving any investigational product in this study
Diagnostic Test: Testing of hepatic AAV Vector integration
Participants have received treatment with fidanacogene elaparvovec in a previous study and are not receiving any investigational product in this study
Diagnostic Test: Testing of hepatic AAV Vector integration
Evaluation of AAV vector integration in participants for whom a sample of liver has been obtained through biopsy or surgical resection when clinically indicated
Incidence of thromboembolic events
Time frame: Day 1 to 10 years
Incidence of factor inhibitor development
FIX inhibitor development was defined as an inhibitor titer \>= 0.6 Bethesda units per milliliter (BU/mL).
Time frame: Day 1 to 10 years
Incidence of hepatic malignancy
Time frame: Day 1 to 10 years
Incidence of liver abnormalities
Time frame: Day 1 to 10 years
Factor activity level
Factor activity level will be reported. Factor levels may be measured using different assay methods including a one-stage assay or by chromogenic substrate assay and a second one-stage assay.
Time frame: Day 1 to 10 years
Total ABR (treated or untreated; (excluding bleeds related to surgery)
ABR (Annual Bleed Rate): number of bleeding episodes per year. This includes treated and untreated bleeds. The ABR or the annualized number of bleeding episodes per year, will be derived for each participant for each observation period by using the following formula: ABR = (Number of bleeds / Days in observation period) x 365.25 days/year.
Time frame: Day 1 to 10 years
Incidence of and time from vector infusion to resumption of prophylaxis
Describe incidence of resumption of prophylaxis resumption and the time (in days) to resumption of prophylaxis after receiving vector infusion.
Time frame: Day 1 to 10 years
AIR of exogenous factor (excluding infusions related to surgery)
The AIR or the annualized number of FIX infusions per year, will be derived for each participant for each observation period by using the following formula: AIR = (Number of FIX infusions / Days in observation period) x 365.25 days/year.
Time frame: Day 1 to 10 years
Consumption of exogenous factor (excluding infusions related to surgery)
The annualized TFC in international units (IU) will be derived for each participant for each observation period using the following formula: Annualized TFC = (Total units of FIX infused (IU)/ Days in observation period) x 365.25 days/year
Time frame: Day 1 to 10 years
Incidence of Non-hepatic malignancy
Time frame: Day 1 to 10 years
Incidence of Auto-immune disorders
Time frame: Day 1 to 10 years
Incidence of SAEs
An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly; development of a clinical thrombotic event; development of factor inhibitor; development of a hepatic malignancy; development of drug-related elevated hepatic transaminases that fail to improve with immunosuppressive regimens; occurrence of a malignancy with reasonable possibility of being related to study drug.
Time frame: Day 1 to 10 years
All cause mortality
All-cause mortality was defined as the death due to any cause during the course of study. Incidence rate was defined as the total number of participants with admissible events divided by the total (for all qualifying participants) time at risk for the cohort/treatment group of interest. Incidence rate of all-cause deaths was reported in this outcome measure.
Time frame: Day 1 to 10 years
EQ-5D-5L dimension and VAS scores
The EQ-5D-5L comprises a 5-item health status measure and a visual analog rating scale/feeling thermometer. Using the 5-dimensional Health State Classification, participants are asked to respond to five questions on different aspects of their health status that assess the following: 1. Mobility 2. Self-care 3. Usual activities 4. Pain/Discomfort 5. Anxiety/Depression
Time frame: Day 1 to 10 years
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Started Dec 2022 (actual). Primary completion is estimated for Feb 2040, 205 months after the start.
Of 89 industry-sponsored phase 3 interventional studies under Hemophilia A, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's planned 205 months is above that.
Counting every sponsor, half of 91 studies reached it within 33 months; a quarter within 20 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
France, Germany, Greece, Japan, Saudi Arabia, Spain, Brazil
France, Germany, Greece, Japan, Saudi Arabia, Spain
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.